SOHO State of the Art Update and Next Questions: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Clinical Lymphoma, Myeloma & Leukemia
Nicholas J ShortElias Jabbour

Abstract

The widespread adoption of Bcr-Abl-directed tyrosine kinase inhibitors (TKIs) into first-line regimens for patients with Philadelphia chromosome (Ph)-positive (Ph+) acute lymphoblastic leukemia (ALL) has revolutionized the outcomes of patients with this disease. Whereas Ph+ ALL was historically associated with cure rates of <25% in the pre-TKI era, now long-term survival in more than 75% of patients has been reported. With the promising efficacy of later-generation TKIs (eg, ponatinib) and the emerging understanding of the prognostic significance of various cooperative genomic alterations and of minimal residual disease, the widespread use of allogeneic hematopoietic stem cell transplantation in first remission for patients with Ph+ ALL has been increasingly questioned. Furthermore, with the development of more potent Bcr-Abl TKIs, several studies are evaluating novel strategies that reduce or eliminate chemotherapy. Herein, we review the major genomic and molecular prognostic factors in Ph+ ALL and also discuss the current and future treatment paradigms for this disease.

Citations

Aug 9, 2019·Journal of Clinical Medicine·Valentina SasUNKNOWN Romanian-Japanese Working Group of the Romanian Society for Bone Marrow Transplantation
Jun 17, 2020·Therapeutic Advances in Hematology·Seth E Karol, Ching-Hon Pui
Jul 2, 2020·Current Hematologic Malignancy Reports·Joselle Cook, Mark Litzow
Oct 20, 2020·Frontiers of Medicine·Ching-Hon Pui
Nov 22, 2018·Therapeutic Advances in Hematology·Jose-Maria RiberaEulalia Genescà
Jul 15, 2021·Expert Opinion on Emerging Drugs·Michela AnsuinelliRobin Foà

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.